GlassScriptPhysician profile
Suzanne M Stragand
NPI 1578787180
$2,664.56
in general payments reported to CMS, 2019-2025
21 companies · $732 in 2025
The $732 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $560 · 2020: $132 · 2021: $237 · 2022: $165 · 2023: $258 · 2024: $582 · 2025: $732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,572.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,571.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,041.67 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $284.80 | 2019-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $269.04 | 2021-2025 | Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $220.40 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $123.74 | 2019-2025 | Otezla, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $113.73 | 2019 | |
| Merck Sharp & Dohme LLC | $111.79 | 2019-2025 | Gardasil 9, Capvaxive, M-M-R II |
| Astrazeneca Pharmaceuticals LP | $102.76 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $71.37 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $66.31 | 2019-2025 | Camzyos, Eliquis |
| Xeris Pharmaceuticals, INC. | $45.58 | 2024-2025 | Keveyis, Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $41.99 | 2024-2025 | Voquezna |
| Ethicon US, LLC | $28.74 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.73 | 2019 | |
| Biogen, INC. | $20.59 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $20.51 | 2025 | Flucelvax, Fluad |
| Neurocrine Biosciences, INC. | $18.63 | 2024 | Ingrezza |
| Insmed, INC. | $18.59 | 2024 | Arikayce |
| Philips North America LLC | $14.79 | 2019 | |
| Ibsa Pharma INC. | $13.78 | 2020 | |
| Sanofi-Aventis U.S. LLC | $11.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Stragand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.